Phase 3 ECHO: Safety Data Review

Efficacy data from the phase 3 EPCORE FL-1 trial evaluating epcoritamab plus rituximab and lenalidomide in this population support the FDA’s decision.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

The developers plan to initiate the TELLOMAK 3 trial, which will evaluate lacutamab in Sézary syndrome and mycosis fungoides, in the first half of 2026.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.